Wells Fargo says Boston Scientific’s CHAMPION-AF trial met all endpoints for WATCHMAN FLX but calls results “good, not great” due to slightly higher stroke rate vs blood thinners.
Boston Scientific (BSX) reports strong Q4 2025 earnings but shares fall over 10% on modest 2026 guidance. Revenue growth expected to slow to 10-11% from 15.8% in 2026.
Boston Scientific announces acquisition of Penumbra for $14.5B, expanding into blood clot removal and neurovascular treatments to address cardiovascular diseases.
